Arkema reports net current earnings of 8.75 euros per share for 2023 (versus 15.75 euros in 2022) and EBITDA down 28.9% to 1.5 billion euros, representing a margin of 15.8% (versus 18.3% in 2022) in a context of weak demand.

The chemical group's sales contracted by 17.6% to 9.51 billion euros, including a 16.1% decline at constant exchange rates and scope of consolidation, with volumes down 10% and a price effect of -6.1%.

A dividend of 3.50 euros per share (versus 3.40 euros in 2022) will be proposed for the past year. Arkema is targeting EBITDA of between €1.5 and €1.7 billion in 2024, with growth to be focused mainly on the second half of the year.

Copyright (c) 2024 CercleFinance.com. All rights reserved.